Share information
267.80 €
+3.60 %
01/04/2026 17:35
+3.60 %
Open
High
Low
Volume
262.60 €
268.20 €
262.50 €
200,864
Latest News
31-Mar-2026
European Commission approves KYGEVVI[®]▼ (doxecitine and doxribtimine) as first and only treatment for Thymidine Kinase 2 Deficiency (TK2d)
27-Mar-2026
UCB announces new BIMZELX[®] (bimekizumab-bkzx) data at AAD showing durable symptom control throughout three years in hidradenitis suppurativa
27-Mar-2026
UCB presents new BIMZELX[®] (bimekizumab-bkzx) data at AAD demonstrating high rates of durable and complete skin clearance in moderate-to-severe plaque psoriasis
27-Mar-2026
Acquisition of own shares